JT Group Launches Ploom AURA and EVO Heated Tobacco Sticks in Japan
Article content
TOKYO — Japan Tobacco Inc. (JT)(TSE:2914) launches Ploom AURA, its next generation heated tobacco device, on May 27, 2025, in Japan, primarily in its Ploom stores and CLUB JT online shop. In parallel, JT Group will roll out EVO, its exclusive and premium heated tobacco sticks (HTS), to complement Ploom AURA and provide adult consumers with the latest and most technologically advanced propositions in the heated tobacco segment. A nationwide launch of Ploom AURA and EVO will start on July 1 in convenience stores and tobacco retail shops. Ploom AURA will roll out globally in the near future.
Article content
The purpose of JT Group's tobacco business is: Creating fulfilling moments. Creating a better future. And with the launch of Ploom AURA in Japan, the world's leading heated tobacco market, JT Group is taking further steps in this direction – bringing to market and adult consumers an innovative and state-of-the-art heated tobacco device, following extensive consumer insights as well as strong research and development.
Article content
'In the Reduced-Risk Products (RRP)* category, we are focusing on providing adult consumers with quality products, rooted in technology, consumer insights, and experience and I truly believe Ploom AURA embraces all these aspects and more. The JT Group will continue to prioritize investments in the heated tobacco sticks segment which maintains the strongest and most consistent growth in the RRP space. Over the course of 2025-2027, we are investing 650 billion yen in RRP, and a significant part of this will be towards Ploom AURA, notably on the launch in Japan and globally,' said Takehiko Tsutsui, Executive Vice President of Reduced-Risk Products.
Article content
Ploom AURA's key focus is on enhancing flavor and the device leverages SMART HEATFLOW heating technology, delivering sensory satisfaction while enabling consumers to enjoy the full essence and richness of tobacco with the absence of combustion and no smell of smoke. The new Heat Select System offers four modes for users to customize their experience in line with their preferences. The device maintains the delicate and organic curves characteristic of Ploom, while evolving into a compact and slim design – combining elegance and practicality.
Article content
EVO is JT Group's global heated tobacco sticks brand, designed to seamlessly enhance Ploom's advanced heating technology and reduced-risk potential. EVO sticks are made from high-quality tobacco leaves, expertly cut and blended to provide a true tobacco taste. An example of meticulous attention to detail, EVO guarantees a satisfying experience with every puff.
Article content
The combination of the cutting-edge technology of Ploom AURA, along with the high-quality EVO heated tobacco sticks, will ensure consumers consistently experience pleasurable heated tobacco moments.
Article content
'The RRP category is reshaping the global tobacco landscape, and I am confident that Ploom AURA and EVO will play key roles in supporting JT Group's ambition of reaching mid-teens share in the HTS segment by 2028,' added Tsutsui.
Article content
*Reduced-Risk Products (RRP): Products with the potential to reduce the risks associated with smoking, such as Heated Tobacco Products, E-Vapor (or vapes), and Oral products like nicotine pouches.
Article content
Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand.
Article content
Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its 'Fulfilling Moments, Enriching Life' purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit https://www.jt.com/.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor and Media Relations Division
Japan Tobacco Inc.
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Merging AI and Quantum Computing: Here's the Stock to Watch
Key Points With its cutting-edge GPUs, Nvidia is a formidable force in the AI industry. Collaborating with quantum computer developers and Japanese researchers, Nvidia is applying its AI capabilities to advance quantum computing. While Nvidia stock seems pricey, it's a no-brainer option for investors seeking both AI and quantum computing exposure. 10 stocks we like better than Nvidia › Bread is great. Meat -- or the vegetarian filling of your choice -- is great, too. But it was the Earl of Sandwich who married the two in the 1700s to create the sandwich as we know it. The race to integrate artificial intelligence (AI) and quantum computing doesn't require the ingenuity of an English nobleman. Today, tech leaders are racing to incorporate the two technologies to revolutionize computing abilities. While Nvidia (NASDAQ: NVDA) is often recognized as an AI industry stalwart, the company is also helping to advance quantum computing, making it a smart choice for those interested in gaining simultaneous exposure to the two burgeoning industries. The company for all AI seasons It's hard to overestimate Nvidia's position as an AI leader, since it has a hand in the varying niches of the AI field. Nvidia AI Foundry, for example, offers customers an end-to-end platform and service for constructing custom generative AI models, including large language models and AI chatbots. Additionally, Nvidia AI Enterprise provides a cloud-native suite of software tools, libraries, and frameworks. Nvidia's graphic processing units (GPUs) provide the backbone for its AI proficiency. The company's latest GPU architecture, Nvidia Blackwell, is in high demand from data centers, where AI computing occurs. Earlier in July, hyperscaler CoreWeave announced that it was "the first cloud provider to deliver this groundbreaking GPU architecture for AI, graphics, and high-performance computing workloads." Like CoreWeave, hyperscaler peer Nebius is rolling out availability to Blackwell architecture to customers, and the company is, unsurprisingly, extremely enthusiastic. In June, Nebius announced that the Blackwell architecture was now available to customers in Europe. With respect to the United States, Nebius is developing a data center in New Jersey that the company plans on singularly dedicating to Nvidia Blackwell-architecture GPUs. Making the quantum leap Unlike companies such as IonQ and Rigetti Computing, which are building actual quantum computers, Nvidia is taking a different -- though necessary -- tack to advancing the nascent field. For one, Nvidia is building a research center in Boston that will integrate its Nvidia GB200 Grace Blackwell superchip (providing advanced AI computing) with quantum computing hardware. The result will be accelerated quantum supercomputing that Nvidia says "will help solve quantum computing's most challenging problems, ranging from qubit noise to transforming experimental quantum processors into practical devices." A qubit is the basic unit of information in quantum computing. Providing 2,020 of its H100 GPUs interconnected by its Quantum-2 InfiniBand networking platform to Japan's National Institute of Advanced Industrial Science and Technology (AIST), Nvidia is also playing a pivotal role in facilitating progress at the ABC1-Q, the world's largest research supercomputer dedicated to quantum computing. In addition, the system is integrated with Nvidia CUDA-Q, an open-source hybrid computing platform that assists hardware and software to conduct enormous quantum computing applications. Speaking to the collaboration between Nvidia and the AIST, Tim Costa, Nvidia's senior director of computer-aided engineering, quantum and CUDA-X, was quoted as saying: Seamlessly coupling quantum hardware with AI supercomputing will accelerate realizing the promise of quantum computing for all. Nvidia's collaboration with AIST will catalyze progress in areas like quantum error correction and applications development -- crucial for building useful, accelerated quantum supercomputers. Is Nvidia a no-brainer buy today for AI and quantum computing exposure? There are several AI leaders and a handful of quantum computing pioneers, however, Nvidia is one of the very few companies developing technologies for both tech fields. This makes it an obvious consideration for those interested in a single investment that provides exposure to both corners of the tech industry. Taking a quick look at the stock's valuation, investors may conclude that shares are pricey now, trading at roughly 56 times trailing earnings. It's important to recognize, though, that Nvidia's position as a semiconductor and AI powerhouse has led to it commanding a higher valuation -- it's five-year average trailing P/E is 70. Therefore, investors shouldn't dismiss the stock as unattractively valued. And though there may be bumps in the road as these two fields mature, Nvidia is an excellent choice for investors looking to be in position to prosper from the growth of AI and quantum computing. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
2 days ago
- Globe and Mail
Mild Cognitive Impairment Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight
The Key Mild Cognitive Impairment Companies in the market include - FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others. DelveInsight's 'Mild Cognitive Impairment Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mild Cognitive Impairment, historical and forecasted epidemiology as well as the Mild Cognitive Impairment market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Mild Cognitive Impairment Market Report: The Mild Cognitive Impairment market size was valued ~USD 2,836 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034). In April 2025, At the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases, Alzheon shared findings from its Phase III APOLLOE4 (NCT04770220) trial during a company-sponsored symposium. The study evaluated ALZ-801 (valiltramiprosate), an oral small molecule that blocks the formation of neurotoxic amyloid beta (Aβ) oligomers, in patients with early-stage Alzheimer's disease—specifically those with mild cognitive impairment (MCI) or mild Alzheimer's—who are homozygous carriers of the APOE4 gene. In December 2024, Blarcamesine (ANAVEX2-73) has been accepted for review by the EMA for the treatment of Alzheimer's disease. This submission was supported by positive findings from the ANAVEX2-73-AD-004 clinical trial, which involved patients in the early stages of Alzheimer's. As of December 2024, TauRx is actively engaging with the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) concerning its UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet aimed at treating mild cognitive impairment due to Alzheimer's (MCI-AD) and mild to moderate Alzheimer's disease. In July 2024, The US FDA has granted approval to KISUNLA (donanemab-azbt, 350 mg/20 mL), an Alzheimer's treatment developed by Eli Lilly. The therapy is intended for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment (MCI) and mild dementia confirmed to have amyloid pathology. In October 2024, AgeneBio reported that its Phase 2B trial of AGB101 showed a 40% reduction in clinical decline and notable slowing of entorhinal cortex atrophy in patients with mild cognitive impairment (MCI) due to Alzheimer's disease who are non-carriers of the ApoE-4 allele, compared to placebo. The ongoing findings from the HOPE4MCI trial strongly support continued evaluation of AGB101 in this specific patient group. The company is currently conducting an extension of the study in the US (NCT05986721). In 2023, the United States held the largest market share for Mild Cognitive Impairment among the 7MM, with an estimated value of around USD 1,467 million, and this figure is projected to grow by 2034. The existing Mild Cognitive Impairment market comprises approved treatments like LEQEMBI (lecanemab) and off-label options such as cholinesterase inhibitors, memantine, and others, collectively reaching a market size of USD 222 million across the 7MM in 2023. In 2023, Japan's Mild Cognitive Impairment market was valued at approximately USD 670 million, representing around 24% of the total 7MM market, with projections indicating further growth by 2034. According to DelveInsight's analysis, the estimated number of diagnosed prevalent cases of Parkinson's disease in the US reached approximately 1.21 million in 2023. In 2023, Germany reported the highest number of diagnosed prevalent Alzheimer's disease cases among European countries, with around 1.49 million cases. France followed with approximately 1.17 million cases, while the UK had the lowest prevalence, with about 620 thousand diagnosed individuals. In Japan, around 2.73 million diagnosed cases of Mild Cognitive Impairment were recorded, with approximately 103,000 linked to Parkinson's disease and about 2.63 million associated with Alzheimer's. Forecasts indicate that by 2034, cases related to Alzheimer's will rise further, continuing to outnumber those related to Parkinson's, emphasizing the growing burden of Alzheimer's on the aging population. According to DelveInsight's analysis, the United States had the highest number of diagnosed prevalent cases of Mild Cognitive Impairment among the 7MM, with approximately 4.22 million cases reported in 2023. However, forecasts suggest that the United Kingdom is expected to surpass others and lead in diagnosed cases by 2034. Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others The Mild Cognitive Impairment market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Cognitive Impairment pipeline products will significantly revolutionize the Mild Cognitive Impairment market dynamics. Mild Cognitive Impairment Overview Between the predicted cognitive loss associated with normal ageing and the more substantial decline associated with dementia is a period known as mild cognitive impairment (MCI). It is characterised by issues with thinking, judgement, language, and memory. Mild Cognitive Impairment Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Mild Cognitive Impairment Epidemiology Segmentation: The Mild Cognitive Impairment market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Mild Cognitive Impairment Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mild Cognitive Impairment market or expected to get launched during the study period. The analysis covers Mild Cognitive Impairment market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Mild Cognitive Impairment Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Mild Cognitive Impairment Therapies and Key Companies LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd. KISUNLA (Donanemab): Eli Lilly and Company Valiltramiprosate (ALZ-801): Alzheon Inc. Mirodenafil (AR1001): AriBio Co., Ltd. Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics T-817MA: FUJIFILM Toyama Chemical Co. Ltd. NYX-458: Aptinyx Aptinyx: AgeneBio T-817MA: FUJIFILM Toyama Chemical Co., Ltd. Aricept (donepezil hydrochloride): Eisai Inc. CX516: RespireRx AL-208: Allon Therapeutics CST-2032: CuraSen Therapeutics, Inc. ladostigil hemitartrate: Avraham Pharma AZD5213: AstraZeneca SAGE-718: Sage Therapeutics fesoterodine: Pfizer MMH-MAP: Materia Medica Holding Donanemab: Eli Lilly and Company Flutemetamol (18F) Injection: GE Healthcare EVP-0962: Parexel Discover more about therapies set to grab major Mild Cognitive Impairment market share @ Mild Cognitive Impairment Treatment Market Scope of the Mild Cognitive Impairment Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others Mild Cognitive Impairment Therapeutic Assessment: Mild Cognitive Impairment current marketed and Mild Cognitive Impairment emerging therapies Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment market drivers and Mild Cognitive Impairment market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Mild Cognitive Impairment Unmet Needs, KOL's views, Analyst's views, Mild Cognitive Impairment Market Access and Reimbursement Table of Contents 1. Mild Cognitive Impairment Market Report Introduction 2. Executive Summary for Mild Cognitive Impairment 3. SWOT analysis of Mild Cognitive Impairment 4. Mild Cognitive Impairment Patient Share (%) Overview at a Glance 5. Mild Cognitive Impairment Market Overview at a Glance 6. Mild Cognitive Impairment Disease Background and Overview 7. Mild Cognitive Impairment Epidemiology and Patient Population 8. Country-Specific Patient Population of Mild Cognitive Impairment 9. Mild Cognitive Impairment Current Treatment and Medical Practices 10. Mild Cognitive Impairment Unmet Needs 11. Mild Cognitive Impairment Emerging Therapies 12. Mild Cognitive Impairment Market Outlook 13. Country-Wise Mild Cognitive Impairment Market Analysis (2020–2034) 14. Mild Cognitive Impairment Market Access and Reimbursement of Therapies 15. Mild Cognitive Impairment Market Drivers 16. Mild Cognitive Impairment Market Barriers 17. Mild Cognitive Impairment Appendix 18. Mild Cognitive Impairment Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Toronto Star
2 days ago
- Toronto Star
Protein Industries Canada and Nurasa Launch Program to Expand Global Reach of Canadian Plant-Based Companies into the Asia-Pacific Market
Singapore, Aug. 01, 2025 (GLOBE NEWSWIRE) — Today at an event in Singapore, witnessed by Minister MacDonald, Minister of Agriculture and Agri-Food Canada, Protein Industries Canada announced a new international partnership with Nurasa, a leading food innovation and commercialization partner based in Singapore. The partnership will help Canadian companies accelerate entry into the fast-growing Asia-Pacific market—one of the world's largest and most dynamic regions for plant-based food innovation. 'Canadian innovation is driving the global shift toward sustainable food solutions.' Said the Honourable Melanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. 'By supporting our plant-based companies as they expand into new markets like the Asia-Pacific, we are helping them scale up, create good jobs at home, and showcase Canadian expertise on the world stage. This partnership is another example of how the Global Innovation Clusters are helping Canadian businesses succeed both at home at abroad, driving Canada's leadership in industries of the future.'
